These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37163883)

  • 41. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
    Dubé S; Dellva MA; Jones M; Kielbasa W; Padich R; Saha A; Rao P
    J Psychiatr Res; 2010 Apr; 44(6):356-63. PubMed ID: 19909980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
    Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
    J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety.
    Fißler M; Quante A
    Complement Ther Med; 2014 Feb; 22(1):63-9. PubMed ID: 24559818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insomnia as a Moderator of Response to Time in Bed Restriction for Augmenting Antidepressant Treatment: A Preliminary Investigation.
    Swanson LM; Huntley ED; Bertram H; Mooney A; Dopp R; Hoffmann R; Armitage R; Arnedt JT
    Behav Sleep Med; 2018; 16(4):315-324. PubMed ID: 27494414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and sociodemographic correlates of severe insomnia in psychotropic drug-free, Asian outpatients with major depressive disorder.
    Srisurapanont M; Likhitsathian S; Chua HC; Udomratn P; Chang S; Maneeton N; Maneeton B; Chen CH; Shih-Yen Chan E; Bautista D; Bin Sulaiman AH
    J Affect Disord; 2015 Nov; 186():26-31. PubMed ID: 26226430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder.
    Shigetsura Y; Imai S; Endo H; Shimizu Y; Ueda K; Murai T; Itohara K; Nakagawa S; Yonezawa A; Ikemi Y; Fukatsu S; Kitada N; Terada T; Nakagawa T; Matsubara K
    Clin Neuropharmacol; 2022 May-Jun 01; 45(3):52-60. PubMed ID: 35579484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression.
    Moderie C; Nuñez N; Fielding A; Comai S; Gobbi G
    Int J Neuropsychopharmacol; 2022 Jun; 25(6):479-488. PubMed ID: 35167671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antidepressants for insomnia in adults.
    Everitt H; Baldwin DS; Stuart B; Lipinska G; Mayers A; Malizia AL; Manson CC; Wilson S
    Cochrane Database Syst Rev; 2018 May; 5(5):CD010753. PubMed ID: 29761479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
    Fava M; Hoog SL; Judge RA; Kopp JB; Nilsson ME; Gonzales JS
    J Clin Psychopharmacol; 2002 Apr; 22(2):137-47. PubMed ID: 11910258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.
    Sakurai H; Suzuki T; Yoshimura K; Mimura M; Uchida H
    Psychopharmacology (Berl); 2017 Aug; 234(16):2453-2461. PubMed ID: 28470399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.
    Maneeton N; Maneeton B; Srisurapanont M; Martin SD
    BMC Psychiatry; 2012 Sep; 12():160. PubMed ID: 23017200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia.
    Manber R; Edinger JD; Gress JL; San Pedro-Salcedo MG; Kuo TF; Kalista T
    Sleep; 2008 Apr; 31(4):489-95. PubMed ID: 18457236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistence of suicidal ideation within acute phase treatment of major depressive disorder: analysis of clinical predictors.
    Olgiati P; Serretti A
    Int Clin Psychopharmacol; 2022 Sep; 37(5):193-200. PubMed ID: 35695646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlates of residual fatigue in patients with major depressive disorder: The role of psychotropic medication.
    Chung KF; Yu YM; Yeung WF
    J Affect Disord; 2015 Nov; 186():192-7. PubMed ID: 26247911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder.
    Rethorst CD; Greer TL; Toups MS; Bernstein I; Carmody TJ; Trivedi MH
    Transl Psychiatry; 2015 Aug; 5(8):e611. PubMed ID: 26241349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].
    Schmitt L; Arbus C; Tonnoir B
    Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.